Table 4.
Characteristic | No. (%) |
---|---|
Age, y, median (range) |
19 (18–22) |
Sex | |
Male |
9 (82) |
Female |
2 (18) |
HAdV type | |
HAdV-4 |
3 (27) |
HAdV-7 |
6 (55) |
Not typed |
2 (18) |
Medical history | |
None |
9 (82) |
Asthma |
1 (9) |
Inflammatory bowel disease |
1 (9) |
Hospital course | |
Intensive care unit admission |
2 (18) |
Radiograph-confirmed pneumonia |
10 (91) |
Initial radiographic findings | |
Single lobar consolidation |
7 (70) |
Multilobar consolidation |
2 (20) |
Bilateral interstitial infiltrate |
1 (10) |
Laboratory findings on admission, median (range) | |
WBC count, K/mm3 (n = 8) |
6.9 (2.4–13) |
Platelet count, K/mm3 (n = 10) |
183.5 (88–198) |
AST level, IU/L (n = 8) |
49 (20–221) |
ALT level, IU/L (n = 8) |
28 (15–422) |
Treatment | |
Antiviral(s) |
4 (36) |
Cidofovir |
2 (18) |
Oseltamivir |
4 (36) |
Antibiotic(s) |
10 (91) |
Intravenous immunoglobulin |
1 (9) |
Intravenous rehydration |
7 (64) |
Highest level of respiratory support | |
None |
7 (64) |
Supplemental oxygen by nasal cannula |
2 (18) |
Extracorporeal membrane oxygenation |
2 (18) |
Concurrent pathogen detections | |
Mycoplasma pneumoniae |
1 (9) |
Epstein-Barr virus |
1 (9) |
No. of days from symptom onset to admission, median (range) |
6 (0–15) |
No. of days hospitalized, median (range) |
4 (1–79) |
Required transfer to a tertiary care center |
3 (27) |
Outcome | |
Died |
2 (18) |
Discharged home |
9 (82) |
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HAdV, human adenovirus; WBC, white blood cell.